VC-backed Surface Oncology appoints chief scientific officer

By Iris Dorbian — 1 week ago

Cambridge, Massachusetts-based Surface Oncology Inc, a developer of next-generation cancer immunotherapies, has named Dr. Vito J. Palombella as chief scientific officer. Previously, Palombella worked at Infinity Pharmaceuticals where he served as executive vice president and chief scientific officer. Surface’s backers include Atlas Venture, Lilly Ventures and New Enterprise Associates.

Continue

VC-backed JenaValve beefs up Munich team with new hire

By Iris Dorbian — 2 weeks ago

JenaValve Technology Inc, a maker of transcatheter aortic valve replacement systems, has named Pieter Van den Steen as chief commercial officer and general manager of the company’s Munich office. Previously, Van den Steen worked at Boston Scientific. JenaValve’s backers included Atlas Venture, Edmond de Rothschild Investment Partners, Gimv, Legend Capital, NeoMed Management, Omega Funds, RMM, Sunstone Capital, Valiance and VI Partners.

Continue

VC-backed Rodin Therapeutics adds Singer to board

By Iris Dorbian — 2 months ago

Cambridge, Massachusetts-based Rodin Therapeutics, a biotech company focused on developing new treatments for neurological disorders, has named Samantha Singer to its board of directors. Singer is the chief operating officer at the Board Institute of MIT and Harvard. Rodin Therapeutics is backed by Atlas Venture.

Continue

Blackbaud buys VC-backed Smart Tuition

By Iris Dorbian — 4 months ago

Blackbaud Inc has acquired Smart Tuition, a provider of payment solutions for private schools and parents, for $190 million. Sagent Advisors LLC served as financial advisor to Blackbaud on the transaction while Raymond James did likewise for Smart Tuition. Smart Tuition’s backers included Atlas Venture, Flybridge Capital Partners and North Hill Ventures.

Continue

Replimune reels in $30 mln Series A

By Iris Dorbian — 4 months ago

UK-based Replimune, a developer of oncolytic immunotherapy, has secured $30 million in Series A funding. Atlas Venture led the round with participation from return backers Forbion Capital Partners and Omega Funds. In addition to the funding, Jason Rhodes of Atlas, Otello Stampacchia of Omega and Sander Slootweg of Forbion have been added to Replimune’s board.

Continue

VC-backed Q4 Web Systems buys Oxford Intelligence Partners

By Iris Dorbian — 5 months ago

Q4 Web Systems has acquired Oxford Intelligence Partners, a provider of stock market intelligence and quantitative trading analytics for investor relations professionals and institutional investors. No financial terms were disclosed. Q4 Web Systems’ is backed by Plaza Ventures, Atlas Venture and Silicon Valley Bank.

Continue

JenaValve scores $26.5 mln Series C

By Iris Dorbian — 6 months ago

JenaValve Technology Inc, a maker of transcatheter aortic valve repair solutions, has closed $26.5 million in Series C funding. RMM and Valiance led the round with participation from other investors that included Atlas Venture, Edmond de Rothschild Investment Partners, Gimv, Legend Capital, NeoMed Management and VI Partners.

Continue

Integral Ad Science pulls in $67 mln

By Iris Dorbian — 6 months ago

New York City-based Integral Ad Science, a provider of advertising intelligence for digital media buyers and sellers, has secured $27 million in funding. Sapphire Ventures led the round with participation from other investors that included Cross Creek Advisors, August Capital, Pelion Venture Partners and Atlas Venture. Also, Silicon Valley Bank provided $40 million in debt funding to Integral.

Continue

Luxury travel deals site Secret Escapes grabs $60 mln

By Iris Dorbian — 6 months ago

London-based Secret Escapes, a luxury travel deals site, has raised $60 million in Series C funding. Google Ventures and Octopus Investments led the round with participation from return backers Index Ventures and Atlas Venture. Torch Partners was the advisor on the transaction.

Continue

RaNA Therapeutics snaps up $55 mln

By Iris Dorbian — 7 months ago

Cambridge, Massachusetts-based RaNA Therapeutics, a RNA-focused drug developer, has closed $55 million in Series B funding. MRL Ventures and the Baupost Group LLC led the round with participation from other investors that included Rock Springs Capital Management, Brookside Capital, Leerink Partners LLC, Atlas Venture, Monsanto, MS Ventures, Omega Funds, Partners Innovation Fund, Pfizer Venture Investments and SR One. In addition to the funding, Dr. Joshua Resnick, president of MRL Ventures, has been added to RaNA’s board of directors.

Continue

Canadian advocate marketing company Influitive snags $30.5 mln

By Iris Dorbian — 7 months ago

Toronto-based advocate marketing company Influitive has raised $30.5 million in Series B funding. Georgian Partners led the round with participation from other investors that included OurCrowd, Atlas Venture, Docomo Capital, BDC Capital IT Venture Fund, Hummer Winblad Venture Partners, Illuminate Ventures, Resolute Ventures, Relay Ventures and First Round Capital. In conjunction with the funding, Simon Chong of Georgian Partners has been added to Influitive’s board of directors.

Continue

New Leaf Venture Partners leads Series B round for Unum Therapeutics

By Iris Dorbian — 8 months ago

Cambridge, Massachusetts-based Unum Therapeutics, a developer of antibody-directed cellular immunotherapy, has closed $65 million in Series B funding. New Leaf Venture Partners led the round with participation from other investors that included Brace Pharma Capital, Cowen Private Investments, Novo A/S, Sabby Management LLC, Wellington Management Company LLP, Fidelity Biosciences, Atlas Venture and Sanofi-Genzyme BioVentures. In addition to the funding, Dr. Liam Ratcliffe, managing director at New Leaf Venture Partners, has been added to Unum’s board of directors.

Continue

Spero Therapeutics fetches $30 mln Series A

By Iris Dorbian — 8 months ago

Cambridge, Massachusetts-based Spero Therapeutics LLC, a biopharmaceutical company that focuses on treating bacterial infections, has raised $30 million in Series A funding. Lundbeckfond Ventures led the round with participation from other investors that included Merck Research Ventures, The Kraft Group, Atlas Venture, SR One and Partners Innovation Fund. In conjunction with the funding, Lundbeckfond Ventures’s Casper Breum and Merck’s Dr. Josh Resnick have been added to Spero’s board.

Continue

PillPack grabs $50 mln in CRV-led round

By Iris Dorbian — 8 months ago

PillPack, a pharmacy that simplifies medication management, has closed $50 million in funding. CRV led the round with participation from Accel Partners, Atlas Venture, Menlo Ventures and Sherpa Ventures. In addition to the funding, George Zachary, a partner at CRV, has been appointed to PillPack’s board.

Continue

VC-backed JenaValve appoints new CEO

By Iris Dorbian — 8 months ago

Munich, Germany and Irvine, California-based JenaValve Technology, a provider of transcatheter aortic valve implantation systems that treat aortic valve disease, has named Dr. Victoria E. Carr-Brendel as CEO. The appointment is effective immediately. Previously, Dr. Carr-Bendel served as general manager of Boston Scientific’s Bayer Interventional business. Its backers include Atlas Venture, Edmond de Rothschild Investment Partners, GIMV, NeoMed Management, Legend Capital, VI Partners, Sunstone Capital, Omega Funds, Biovest and Valiance Advisors.

Continue

Programmatic TV startup Clypd pulls in $19.4 mln

By Iris Dorbian — 10 months ago

Boston-based programmatic TV startup Clypd has raised $19.4 million in Series B funding. RTL Group led the round with participation from Atlas Venture, Data Point Capital, Duke University, TiVo Inc, Transmedia Capital and Western Technology Investment.

Continue